Evidence map›Paper›PMID 41134344›Full record

ReviewActa diabetologica2026

Investigating the role of IGF-1 in diabetic gastroparesis: a preliminary review.

Yifan Lu, Wei Wei, Hao Chen, Yixuan Xie, Jie Tian, Ziming Zhao, Qibiao Wu, Xiqiao Zhou

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yifan LuState Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China.ORCID http://orcid.org/0009-0001-3564-8232
Wei WeiDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, Jiangsu, China.
Hao ChenDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, Jiangsu, China.
Yixuan XieDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, Jiangsu, China.
Jie TianSchool of Nursing, Nanjing University of Chinese Medicine, Nanjing, China.
Ziming ZhaoState Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China.
Qibiao WuState Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China. qbwu@must.edu.mo.
Xiqiao ZhouDepartment of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, Jiangsu, China. zhouxiqiao@njucm.edu.cn.

Funding

the Fatty Liver clinical medicine innovation center of integrated traditional Chinese and Western medicine K2023yzx07
6 · The paper itself

Abstract

Diabetic gastroparesis is characterized by delayed gastric emptying due to diabetes mellitus, affecting up to 50% of patients with type 1 and type 2 diabetes who have poor glycemic control, significantly impairing their quality of life. IGF-1 presents significant potential as a therapeutic target for DGP due to its neuroprotective effects and its role in inhibiting smooth muscle cell apoptosis. By promoting the survival and regeneration of interstitial cells of Cajal and reducing inflammation, IGF-1 could enhance gastrointestinal regulation, thereby improving gastric motility and alleviating DGP symptoms. Although IGF-1 has not yet been utilized as a targeted therapy for DGP, its ability to modulate key signaling pathways, such as SCF/C-Kit, PI3K/AKT, and ERK/MAPK, suggests promising therapeutic avenues. Future research should focus on investigating these mechanisms to determine IGF-1's precise role in DGP pathophysiology and explore its clinical applications.

Indexed as

Diabetes ComplicationsDiabetes Mellitus, Type 1GastroparesisInsulin-Like Growth Factor IAnimalsGastric EmptyingHumansSignal TransductionInsulin-Like Growth Factor IDiabetic gastroparesisERK/MAPK pathwayIGF-1Interstitial cells of cajalPI3K/AKT pathwaySmooth muscle cellsStem cell factor

Identifiers

PMID41134344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.